DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform

DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform

Genentech taps DualityBio's DUPAC ADC payload platform in a $45M upfront, $1B+ milestone deal to target payload-resistant tumors.